IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

PALLA, ROBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.908
NA - Nord America 5.802
AS - Asia 5.227
SA - Sud America 523
AF - Africa 155
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 12
Totale 18.655
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.550
GB - Regno Unito 2.382
SG - Singapore 1.634
CN - Cina 1.479
IT - Italia 1.078
DE - Germania 814
SE - Svezia 718
RU - Federazione Russa 493
HK - Hong Kong 425
BD - Bangladesh 377
BR - Brasile 352
VN - Vietnam 319
FR - Francia 293
IN - India 270
NL - Olanda 237
TR - Turchia 230
UA - Ucraina 213
IE - Irlanda 172
CA - Canada 160
FI - Finlandia 141
KR - Corea 140
EU - Europa 127
JP - Giappone 81
CO - Colombia 68
ES - Italia 66
ID - Indonesia 61
MX - Messico 55
DK - Danimarca 51
PL - Polonia 51
AR - Argentina 50
IR - Iran 43
BE - Belgio 41
CI - Costa d'Avorio 34
CH - Svizzera 33
EG - Egitto 29
IQ - Iraq 28
TN - Tunisia 27
AU - Australia 26
GR - Grecia 23
PK - Pakistan 21
AT - Austria 14
EC - Ecuador 13
ZA - Sudafrica 13
MY - Malesia 12
PT - Portogallo 12
TH - Thailandia 12
AE - Emirati Arabi Uniti 11
CL - Cile 11
UZ - Uzbekistan 11
KE - Kenya 10
PH - Filippine 10
AZ - Azerbaigian 9
HU - Ungheria 9
JO - Giordania 9
MA - Marocco 9
PE - Perù 9
RO - Romania 9
JM - Giamaica 8
NP - Nepal 8
SA - Arabia Saudita 8
SK - Slovacchia (Repubblica Slovacca) 8
LU - Lussemburgo 7
CR - Costa Rica 6
DZ - Algeria 6
NO - Norvegia 6
VE - Venezuela 6
HR - Croazia 5
PY - Paraguay 5
SC - Seychelles 5
TW - Taiwan 5
UY - Uruguay 5
AL - Albania 4
BG - Bulgaria 4
BO - Bolivia 4
KZ - Kazakistan 4
LT - Lituania 4
NG - Nigeria 4
PA - Panama 4
SN - Senegal 4
TT - Trinidad e Tobago 4
GT - Guatemala 3
KW - Kuwait 3
LB - Libano 3
MD - Moldavia 3
MU - Mauritius 3
SV - El Salvador 3
AF - Afghanistan, Repubblica islamica di 2
BY - Bielorussia 2
DJ - Gibuti 2
IL - Israele 2
KG - Kirghizistan 2
LV - Lettonia 2
ME - Montenegro 2
MK - Macedonia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
OM - Oman 2
PR - Porto Rico 2
RS - Serbia 2
TM - Turkmenistan 2
Totale 18.745
Salva come PNG Salva come JPEG
Città #
Southend 2.127
Singapore 981
Ashburn 537
Chandler 427
Hong Kong 385
Milan 380
San Jose 352
Beijing 296
Seattle 275
Hanover 247
Dallas 246
Princeton 230
Wilmington 210
Jacksonville 186
Council Bluffs 182
Dublin 172
Los Angeles 145
Santa Clara 145
Ann Arbor 139
Bengaluru 121
Fairfield 121
New York 114
Mountain View 112
Nanjing 111
Lauterbourg 101
Ho Chi Minh City 98
Boardman 95
Redmond 95
Houston 82
Dearborn 81
Buffalo 79
Woodbridge 77
Ottawa 75
Hanoi 73
Shanghai 72
Frankfurt am Main 68
Guangzhou 67
Des Moines 65
Somerville 65
Moscow 64
Sakarya 62
Hefei 61
Bogotá 60
Serra 60
Andover 55
Rome 54
Tokyo 54
Cambridge 51
Istanbul 47
Cangzhou 41
Jinan 41
Helsinki 40
Nanchang 40
Pisa 40
São Paulo 39
Berlin 38
Munich 38
Tianjin 36
Warsaw 34
Abidjan 33
Phoenix 33
Brussels 32
Jakarta 30
Redwood City 30
Centro 29
Shenyang 29
Turin 26
Seoul 25
Toronto 25
Zhengzhou 25
Düsseldorf 23
Fuzhou 23
Kunming 23
Columbus 22
Saint Petersburg 22
Athens 21
Naples 21
The Dalles 21
London 20
Mumbai 20
Roxbury 20
Bitonto 19
Da Nang 19
Hebei 19
Montreal 19
Ankara 18
Orem 18
San Diego 18
Hangzhou 17
Madrid 17
Turku 17
Boston 16
Changsha 16
Chicago 16
Medford 16
Jiaxing 15
Atlanta 14
Bologna 13
Eitensheim 13
Haiphong 13
Totale 11.255
Salva come PNG Salva come JPEG
Nome #
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis 577
Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders 521
Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A 476
European Network of Rare Bleeding Disorders (EN-RBD) 384
Thrombotic Thrombocytopenic Purpura (TTP) Database 322
Risk factors for recurrence of thrombotic thrombocytopenic purpura 319
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis 292
Genetic diagnosis of haemophilia and other inherited bleeding disorders 273
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura 273
International Rare Bleeding Disorders Database 264
ADAMTS13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura 258
The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome 257
Molecular mapping of the chloride binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS1-13 252
Hemostatic alterations in COVID-19 247
Genetics of rare bleeding disorders 246
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission 244
Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity 243
An international registry of patients with plasminogen deficiency (HISTORY) 242
ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura 238
Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13 234
Database on rare bleeding disorder (RBDS) : phenotype and genotype analysis on 400 affected patients 230
B and T lymphocytes in acquired thrombotic thrombocytopenic purpura during disease remission 222
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry 222
Molecular mapping of the chloride binding site in von Willebrand factor (VWF) : energetics and conformational effects on the ADAMTS-13 interaction with wild type and type 2B R1306W VWF forms 219
Determination of anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura (TTP) patients : comparison of two different methods 215
Comparison of assays to evaluate ADAMTS13 activity in patients’ plasma 214
The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPET Cohort 214
Different clinical severity of first episodes and recurrence of thrombotic thrombocytopenic purpura 213
Evaluation of assays to measure ADAMTS13 activity in patients' plasma 212
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database 204
Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura 202
State of the art of rare bleeding disorders database (RBDD) 202
FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients 201
Rare bleeding disorders 201
Future perspective of international registry on rare inherited bleeding disorder 196
Establishment of a European network of Rare Bleeding Disorders (RBDs) 193
Platelet ADAMTS13 and in vitro expression study of a patient affected by congenital TTP 192
ADAMTS-13 assays in thrombotic thrombocytopenic purpura 192
Molecular mapping of chloride binding site in VWF : energetics and conformational effects on the VWF/ADAMTS-13 interaction 190
The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pK(a) value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding 190
Microangiopatie trombotiche 188
The First Deletion Mutation in the TSP1-6 Repeat Domain of ADAMTS13 Leads to a Secretion Defect 185
The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 leads to a secretion defect 185
Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3' untranslated region of the factor VII (FVII) gene : molecular characterization of a patient with severe FVII deficiency 179
Introduction. Rare bleeding disorders : general aspects of clinical features, diagnosis, and management 179
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A 177
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A 175
Kinetics studies of a naturally occurring mutation on Factor X (FX) gene (G222D) 174
Modulators of Von Willebrand factor (VWF) multimers size in thrombotic processes 173
Ristocetin accelerates Von Willebrand Factor (VWF) hydrolysis rate and ameliorates Collagen Binding Assay (CBA) sensitivity 168
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders : results from the European Network of Rare Bleeding Disorders 167
Measurement of anti-ADAMTS13 neutralising autoantibodies: a comparison between CBA and FRET assays 167
The thrombospondin-1 N700S polymorphism does not alter von Willebrand Factor multimer size in patients suffering an acute myocardial infarction 163
No changes of parameters nor coagulation activation in healthy subjects vaccinated for {SARS}-Cov-2 163
The natural VWF mutant P.R1306W, causing a type 2B VWD, binds, chloride ions with lower affinity than WT VWD and is cleaved more efficently by ADAMTS-13 161
Localization and Function of Platelet ADAMTS-13 160
European registry of rare bleeding disorders 156
Two adjacent homozygous mutations on EGF2 domain of factor X (FX) gene lead to severe FX deficiency 155
The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency 154
Patients Informative Booklet on the Women with rare bleeding disorders project 154
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size 153
Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency-misdiagnosis by direct sequence analysis using a PCR product 153
Establishment of a European network of rare bleeding disorders 152
Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management 151
Perturbation of pKa values of catalytic residues in the NATURAL thrombin : mutant with deletion of Lys9 in the A-chain 151
Diagnosis of FXIII deficiency: data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories 151
Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13) 150
Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies 150
Factor XIII deficiency : preliminary results of the PRO-RBDD project 150
The thrombospondin-1 N700S polymorphism does not alter von Willebrand factor multimer size in patients suffering an acute myocardial infarction 149
Lombardy diagnostic and therapeutic network of thrombotic microangiopathy 147
Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies 146
Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis 146
Thrombospondin-1 as a modulator of ADAMTS13 activity 146
Risk factors for inhibitor development in severe hemophilia A 145
Mechanistic studies on ADAMTS13 catalysis 143
Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction 142
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A 140
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort 139
A recurrent Gly43Asp substitution of coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking 137
Future perspective of international registry on rare inherited bleeding disorder 132
Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories 130
SIPPET: methodology, analysis and generalizability 128
Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories 126
Lombardy Network for the Study and Treatment of Patients Undergoing Apheresis 124
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" 123
Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency 123
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13 : a new prothrombotic mechanism in diseases associated with oxidative stress 122
Rare bleeding disorders: diagnosis and treatment 122
Effect of pH and temperature on ADAMTS-13 catalysis 119
Registri nazionali ed internazionali sulle malattie rare della coagulazione 113
Combined Factor V and Factor VIII Deficiency in Rare Coagulation Disorders 112
Patients Informative Booklet on the Establishment of a European Network of Rare Bleeding Disorders (EN-RBD) project funded by EC (downloadable at www.rbdd.eu) 111
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates 107
Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey 104
Fibrinogen concentrates 102
Lombardy network for the study and treatment of patients undergoing apheresis 101
Gynecologic and obstetric complications in women with congenital fibrinogen disorders: insights from the Prospective Rare Bleeding Disorders Database 100
Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired) 99
Diagnostic relevance of ADAMTS13 activity : evaluation of 28 patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome clinical diagnosis 99
Totale 18.907
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202172 0 0 0 0 0 0 0 0 0 0 0 72
2021/20221.442 104 64 41 123 106 77 120 88 115 154 157 293
2022/20231.733 254 184 132 161 190 330 24 171 142 31 69 45
2023/2024819 37 90 39 39 175 89 30 49 15 42 89 125
2024/20252.514 124 272 76 241 150 80 91 281 149 245 211 594
2025/20265.596 521 273 535 555 543 364 640 268 513 413 566 405
Totale 19.575